Tumour Progression Related News
CINSW presents Premier’s Awards to two Garvan Researchers
MEDIA RELEASE:
15 Jul 2011
At a gala dinner held last night, the Cancer Institute NSW presented Dr Alex Swarbrick with the CINSW 2011 Premier’s Fellow of the Year Award and Dr David Chang with the CINSW 2011 Premier’s Scholar of the Year Award, as well as a Pfizer Oncology International Studentship.
Silencing a deadly conversation in breast cancer
MEDIA RELEASE:
02 Jun 2011
Garvan researchers have shown that a molecule known as ‘hedgehog’ sits at the centre of a cellular 'switchboard' in breast cancer, transmitting biochemical signals between the cancer cells and the healthy cells nearby. They have identified a new way of turning off this cellular cross talk - which would otherwise allow the cancer to thrive. This off switch offers a potential therapeutic, especially for women with cancers that do not respond to current treatments.
A new way of reversing certain cancers
MEDIA RELEASE:
27 Sep 2010
Australian and American scientists have identified a particular microRNA (a recently discovered class of gene) as a therapeutic target in treating certain cancers, such as the childhood neural cancers known as 'neuroblastomas', some melanomas and some brain cancers. The microRNA appears to disable the king of tumour suppressors, the P53 gene. Findings in mice show that blocking the microRNA can restore P53 production and shrink tumours.
Garvan and St Vincent’s to Build $100 million Australian Cancer Centre
MEDIA RELEASE:
22 Oct 2008
The Garvan Institute of Medical Research and St Vincents & Mater Health Sydney will today announce plans to jointly establish a new $100 million Cancer Centre within the St Vincent’s Research Precinct. The Garvan St Vincent’s Campus Cancer Centre (GSVCCC) will integrate internationally acclaimed cancer research with best practice cancer services, enabling research findings to move quickly into patient care.
Targeting aggressive breast cancers by putting them to sleep
MEDIA RELEASE:
25 Mar 2008
Dr Alex Swarbrick, head of Garvan's Tumour Progression Research Group, has published findings that Id1, a gene produced by the most aggressive forms of breast cancer, can control breast cancer growth. He has shown that by 'switching off' the Id1 gene, it is possible to induce a state of 'senescence', or permanent sleep, within a tumour, preventing it from growing or spreading.
